Important lessons have been learned in the use of injectable PLLA that have helped reduce the frequency of adverse events and make it desirable for restoring facial volume (Table 1). The importance of diffuse distribution of the injectable PLLA suspension
Different injectable products have highly divergent properties, associated risks, and injection requirements. The der- masurgeon should be suitably experienced to select and use these products correctly.
At week 24, mean improvement in WSRS from baseline was 2.09 0.68 for the PLA side and 1.54 0.65 for the HA side. Both injections were well toler- ated, and the adverse reactions were mild and transient in most cases. PLA provides noninferior efficac
